IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A method for the prophylaxis and/or treatment of one or more diseases or disorders, selected from autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, graft rejection or lung injuries, comprising, administering to a subject in need thereof, an effective amount of ~~Use of~~ a compound of ~~according to~~ formula (I):



(I)

as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof, wherein

A is a 5-8 membered heterocyclic or carbocyclic group, wherein said carbocyclic group may be fused with aryl, heteroaryl, cycloalkyl or heterocycloalkyl;

X is S, O or NH;

Y^1 and Y^2 are independently S, O or ~~NH~~ NH;

Z is S or O;

R^1 is H, CN, carboxy, acyl, C_1-C_6-alkoxy, halogen, hydroxy, acyloxy, C_1-C_6-alkyl carboxy, C_1-C_6-alkyl acyloxy, C_1-C_6-alkyl alkoxy, alkoxycarbonyl, C_1-C_6-alkyl alkoxycarbonyl, aminocarbonyl, C_1-C_6-alkyl aminocarbonyl, acylamino, C_1-C_6-alkyl acylamino, ureido, C_1-C_6-alkyl ureido, amino, C_1-C_6-alkyl amino, ammonium, sulfonyloxy,

C_1-C_6-alkyl sulfonyloxy, sulfonyl, C_1-C_6-alkyl sulfonyl, sulfinyl, C_1-C_6-alkyl sulfinyl, sulfanyl, C_1-C_6-alkyl sulfanyl, sulfonylamino, C_1-C_6-alkyl sulfonylamino or carbamate;

R^2 is selected from the group ~~comprising or~~ consisting of H, halogen, acyl, amino, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_6-alkyl carboxy, C_1-C_6-alkyl acyl, C_1-C_6-alkyl alkoxycarbonyl, C_1-C_6-alkyl aminocarbonyl, C_1-C_6-alkyl acyloxy, C_1-C_6-alkyl acylamino, C_1-C_6-alkyl ureido, C_1-C_6-alkyl amino, C_1-C_6-alkyl alkoxy, C_1-C_6-alkyl sulfanyl, C_1-C_6-alkyl sulfinyl, C_1-C_6-alkyl sulfonyl, C_1-C_6-alkyl sulfonylaminoaryl, aryl, C_3-C_8-cycloalkyl or heterocycloalkyl, C_1-C_6-alkyl aryl, C_2-C_6-alkenyl-aryl, C_2-C_6-alkynyl aryl, carboxy, cyano, hydroxy, C_1-C_6-alkoxy, nitro, acylamino, ureido, C_1-C_6-alkyl carbamate, sulfonylamino, sulfanyl, or sulfonyl;

n is 0, 1 or 2;

~~for the preparation of a medicament for the prophylaxis and/or treatment of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, graft rejection or lung injuries;~~

with the proviso that the following compounds are excluded:



(TE)



(JA)

wherein R^1 is a lower alkyl or aralkyl and R^2 is H or a halogen.

Claim 2 (Currently Amended): The method ~~Use of a compound~~ according to claim 1, wherein said one or more diseases are selected from ~~in~~ the group consisting of ~~including~~ multiple sclerosis, psoriasis, rheumatoid arthritis, ~~multiple sclerosis~~[[,]] systemic lupus erythematosis, inflammatory bowel disease, lung inflammation, and thrombosis or brain infection/inflammation such as meningitis or encephalitis.

Claim 3 (Currently Amended): The method ~~Use of a compound~~ according to claim 1, wherein said one or more diseases are selected from ~~in~~ the group consisting of ~~including~~ Alzheimer's disease, Huntington's disease, CNS trauma, stroke and ~~or~~ ischemic conditions.

Claim 4 (Currently Amended): The method ~~Use of a compound~~ according to claim 1, wherein said one or more diseases are selected from ~~in~~ the group consisting of ~~including~~ atherosclerosis, heart hypertrophy, cardiac myocyte dysfunction, elevated blood pressure and ~~or~~ vasoconstriction.

Claim 5 (Currently Amended): The method ~~Use of a compound~~ according to claim 1, wherein said one or more diseases or disorders are selected from ~~in~~ the group consisting of ~~including~~ chronic obstructive pulmonary disease, anaphylactic shock fibrosis, psoriasis, allergic diseases, asthma, stroke or ischemic conditions, ischemia reperfusion, platelets aggregation/activation, skeletal muscle atrophy/hypertrophy, leukocyte recruitment in cancer tissue, pancreatitis, multiorgane failure, angiogenesis, invasion metastisis, ~~in particular~~ melanoma, Karposi's sarcoma, acute and chronic bacterial and viral infections, sepsis, transplantation graft rejection, glomerulo sclerosis, glomerulo nephritis, progressive renal fibrosis, endothelial and epithelial injuries in the lung and ~~or in~~ general lung airways inflammation.

Claim 6 (Currently Amended): The method ~~Use~~ according to claim 1 ~~any of the precedent claims~~, wherein Y^1 and Y^2 are both oxygen.

Claim 7 (Currently Amended): The method ~~Use~~ according to claim 1 ~~any of the precedent claims~~, wherein n is 1 or 2 and R^1 and R^2 are both H.

Claim 8 (Currently Amended): The method ~~Use of compounds~~ according to claim 1 ~~any of the preceding claims~~, wherein, in the compound of formula (I), X is S, Y^1 and Y^2 are both O, ~~R^1 and R^2 are as above defined~~ and n is 0.

Claim 9 (Currently Amended): The method ~~Use~~ according to claim 1 ~~any of the precedent claims~~, whereby the compound of formula (I) is a thiazolidinone-vinyl fused-benzene derivative of ~~has~~ the formula (Ia)



(Ia)

wherein Y^1, R^1, R^2, Z and n are as above defined for the compound of formula (I);

V and W are each, independently from each other, O, S or $-NR^3$ wherein R^3 is H or C_1-C_6 alkyl;

G is a C_1-C_5 alkylene or a C_1-C_5 alkenylene group;

o and m are each, independently from each other, 0 or 1; and

q is an integer from 0 to 4.

Claim 10 (Currently Amended): The method ~~Use~~ according to claim 9, whereby the thiazolidinone-vinyl fused-benzene derivative has the formula (Ib):



(Ib)

wherein Y^1, R^1, R^2, V, Z, W, m, n, o, q are as above defined in the compound of formula (Ia), and p is an integer from 1 to 4.

Claim 11 (Currently Amended): The method ~~Use~~ according to claim 9 ~~any of claims 9 or 10~~, whereby the thiazolidinone-vinyl fused-benzene derivative has the formula (Ic):



(Ic)

wherein W, as well as R^1 and Y^1, are as above defined in the compound of formula (Ia).

Claim 12 (Currently Amended): The method ~~Use~~ according to claim 9 ~~any of claims 9 or 10~~, whereby the thiazolidinone-vinyl fused-benzene derivative has the formula (Id):



(Id)

wherein R^1, R^2, Z and n are as above defined in formula (Ia); o is 0 or 1;

p is an integer from 1 to 4 and q is an integer from 0 to 4.

Claim 13 (Currently Amended): The method ~~Use of compounds~~ according to claim 9, ~~any of claims 9, 10 or 12~~ wherein, in formula (Ia), Z is O, m is 0, n is l, p is 1 or 2, q is 1, and R^1 and R^2 are each as above defined for the compound of formula (Ia).

Claim 14 (Currently Amended): The method ~~Use of compounds~~ according to claim 9, ~~any of claims 9, 10 or 12~~ wherein, in formula (Ia), m is 1, n is 0, p is 1 or 2, q is 0, and R^1 and R^2 are each as above defined for the compound of formula (Ia).

Claim 15 (Currently Amended): The method ~~Use~~ according to claim 9, ~~any of claims 9, 10 and 12 to 14~~ wherein, in formula (Ia), m is 0, n is 1, p is 1 or 2, q is 0, and R^1 and R^2 are each as defined above ~~in claim 1~~ for the compound of formula (I).

Claim 16 (Currently Amended): The method ~~Use~~ according to claim 9, ~~any of claims 9, 10 and 12 to 14~~ wherein, in formula (Ia), R^1 is halogen or hydrogen.

Claim 17 (Currently Amended): A method for the prophylaxis and/or treatment of one or more diseases mediated by PI3 kinase, comprising administering to a subject in need thereof, an effective amount of a compound of formula (I): ~~Use according to any of claims 1 to 16 for the modulation, in particular for the inhibition, of the PI3 kinase activity~~



(I)

as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof, wherein

A is a 5-8 membered heterocyclic or carbocyclic group, wherein said carbocyclic group may be fused with aryl, heteroaryl, cycloalkyl or heterocycloalkyl;

X is S, O or NH;

Y^1 and Y^2 are independently S, O or NH;

Z is S or O;

R^1 is H, CN, carboxy, acyl, C_1-C_6-alkoxy, halogen, hydroxy, acyloxy, C_1-C_6-alkyl carboxy, C_1-C_6-alkyl acyloxy, C_1-C_6-alkyl alkoxy, alkoxycarbonyl, C_1-C_6-alkyl alkoxycarbonyl, aminocarbonyl, C_1-C_6-alkyl aminocarbonyl, acylamino, C_1-C_6-alkyl acylamino, ureido, C_1-C_6-alkyl ureido, amino, C_1-C_6-alkyl amino, ammonium, sulfonyloxy, C_1-C_6-alkyl sulfonyloxy, sulfonyl, C_1-C_6-alkyl sulfonyl, sulfinyl, C_1-C_6-alkyl sulfinyl, sulfanyl, C_1-C_6-alkyl sulfanyl, sulfonylamino, C_1-C_6-alkyl sulfonylamino or carbamate;

R^2 is selected from the group consisting of H, halogen, acyl, amino, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_6-alkyl carboxy, C_1-C_6-alkyl acyl, C_1-C_6-alkyl

alkoxycarbonyl, C_1-C_6-alkyl aminocarbonyl, C_1-C_6-alkyl acyloxy, C_1-C_6-alkyl acylamino, C_1-C_6-alkyl ureido, C_1-C_6-alkyl amino, C_1-C_6-alkyl alkoxy, C_1-C_6-alkyl sulfanyl, C_1-C_6-alkyl sulfinyl, C_1-C_6-alkyl sulfonyl, C_1-C_6-alkyl sulfonylaminoaryl, aryl, C_3-C_8-cycloalkyl or heterocycloalkyl, C_1-C_6-alkyl aryl, C_2-C_6-alkenyl-aryl, C_2-C_6-alkynyl aryl, carboxy, cyano, hydroxy, C_1-C_6-alkoxy, nitro, acylamino, ureido, C_1-C_6-alkyl carbamate, sulfonylamino, sulfanyl, and sulfonyl;

n is 0, 1 or 2;

with the proviso that the following compounds are excluded



(TE)



(JA)

wherein R^1 is a lower alkyl or aralkyl and R^2 is H or a halogen.

Claim 18 (Currently Amended): The method ~~Use~~ according to claim 17, wherein said PI3 kinase is a PI3 kinase γ.

Claim 19 (Currently Amended): A thiazolidinone-vinyl fused-benzene derivative according to formula (II-a):



(II-a)

wherein A is selected from the group consisting of dioxol, dioxin, dihydrofuran, (dihydro) furanyl, (dihydro)oxazinyl, pyridinyl, isooxazolyl, oxazolyl (dihydro)napthalenyl, pyrimidinyl, triazolyl, imidazolyl, pyrazinyl, thiazolidinyl, thiadiazolyl, and oxadiazolyl;

R^2 is selected from the group ~~comprising or~~ consisting of H, halogen, acyl, amino, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkenyl, C_1-C_6-alkyl carboxy, C_1-C_6-alkyl acyl, C_1-C_6-alkyl alkoxycarbonyl, C_1-C_6-alkyl aminocarbonyl, C_1-C_6-alkyl acyloxy, C_1-C_6-alkyl acylamino, C_1-C_6-alkyl ureido, C_1-C_6-alkyl carbamate, C_1-C_6-alkyl amino, C_1-C_6-alkyl alkoxy, C_1-C_6-alkyl sulfanyl, C_1-C_6-alkyl sulfinyl, C_1-C_6-alkyl sulfonyl, C_1-C_6-alkyl sulfonylaminoaryl, aryl, C_3-C_8-cycloalkyl or heterocycloalkyl, C_1-C_6-alkyl aryl, C_2-C_6-alkenyl-aryl, C_2-C_6-alkynyl aryl, carboxy, cyano, hydroxy, C_1-C_6-alkoxy, nitro, acylamino, ureido, sulfonylamino, sulfanyl, and ~~or~~ sulfonyl.

Claim 20 (Currently Amended): A thiazolidinone-vinyl fused-benzene derivative according to formula (II):



(II)

as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof, wherein

Y^1 is S, O or NH;

Z is S or O;

R^1 is H, CN, carboxy, acyl, C_1-C_6-alkoxy, halogen, hydroxy, acyloxy, C_1-C_6-alkyl carboxy, C_1-C_6-alkyl acyloxy, C_1-C_6-alkyl alkoxy, alkoxycarbonyl, C_1-C_6-alkyl alkoxycarbonyl, aminocarbonyl, C_1-C_6-alkyl aminocarbonyl, acylamino, C_1-C_6-alkyl acylamino, ureido, C_1-C_6-alkyl ureido, amino, C_1-C_6-alkyl amino, ammonium, sulfonyloxy, C_1-C_6-alkyl sulfonyloxy, sulfonyl, C_1-C_6-alkyl sulfonyl, sulfinyl, C_1-C_6-alkyl sulfinyl, sulfanyl, C_1-C_6-alkyl sulfanyl, sulfonylamino, C_1-C_6-alkyl sulfonylamino or carbamate;

R^2 is selected from the group consisting of H, halogen, acyl, amino, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_6-alkyl carboxy, C_1-C_6-alkyl acyl, C_1-C_6-alkyl alkoxycarbonyl, C_1-C_6-alkyl aminocarbonyl, C_1-C_6-alkyl acyloxy, C_1-C_6-alkyl acylamino, C_1-C_6-alkyl ureido, C_1-C_6-alkyl amino, C_1-C_6-alkyl alkoxy, C_1-C_6-alkyl sulfanyl, C_1-C_6-alkyl sulfinyl, C_1-C_6-alkyl sulfonyl, C_1-C_6-alkyl sulfonylaminoaryl, aryl, C_3-C_8-cycloalkyl or heterocycloalkyl, C_1-C_6-alkyl aryl, C_2-C_6-alkenyl-aryl, C_2-C_6-alkynyl aryl, carboxy, cyano, hydroxy, C_1-C_6-alkoxy, nitro, acylamino, ureido, C_1-C_6-alkyl carbamate, sulfonylamino, sulfanyl, and sulfonyl;

n is 0 or 1

~~Z, Y^1, R^1, R^2 are as above defined, n is 0 or 1~~.

Claim 21 (Currently Amended): The ~~A~~ thiazolidinone-vinyl fused-benzene derivative according to claim 20, wherein Y^1 is O.

Claim 22 (Currently Amended): The ~~A~~ thiazolidinone-vinyl fused-benzene derivative according to claim 20 ~~any claims 20 or 21~~, wherein R^1 is selected from ~~in~~ the group consisting of C_1-C_6-alkyl, C_1-C_6-alkyl aryl, aryl, C_3-C_8-cycloalkyl or heterocycloalkyl, C_1-C_6-alkyl aryl, C_2-C_6-alkenyl-aryl and ~~or~~ C_2-C_6-alkynyl aryl.

Claim 23 (Currently Amended): A thiazolidinone-vinyl fused-benzene derivative according to formula (III):



(III)

as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof, and wherein

R^1 is H, CN, carboxy, acyl, C_1-C_6-alkoxy, halogen, hydroxy, acyloxy, C_1-C_6-alkyl carboxy, C_1-C_6-alkyl acyloxy, C_1-C_6-alkyl alkoxy, alkoxycarbonyl, C_1-C_6-alkyl alkoxycarbonyl, aminocarbonyl, C_1-C_6-alkyl aminocarbonyl, acylamino, C_1-C_6-alkyl acylamino, ureido, C_1-C_6-alkyl ureido, amino, C_1-C_6-alkyl amino, ammonium, sulfonyloxy, C_1-C_6-alkyl sulfonyloxy, sulfonyl, C_1-C_6-alkyl sulfonyl, sulfinyl, C_1-C_6-alkyl sulfinyl, sulfanyl, C_1-C_6-alkyl sulfanyl, sulfonylamino, C_1-C_6-alkyl sulfonylamino or carbamate;

R^2 is selected from the group consisting of H, halogen, acyl, amino, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_6-alkyl carboxy, C_1-C_6-alkyl acyl, C_1-C_6-alkyl

alkoxycarbonyl, C_1-C_6-alkyl aminocarbonyl, C_1-C_6-alkyl acyloxy, C_1-C_6-alkyl acylamino, C_1-C_6-alkyl ureido, C_1-C_6-alkyl amino, C_1-C_6-alkyl alkoxy, C_1-C_6-alkyl sulfanyl, C_1-C_6-alkyl sulfinyl, C_1-C_6-alkyl sulfonyl, C_1-C_6-alkyl sulfonylaminoaryl, aryl, C_3-C_8-cycloalkyl or heterocycloalkyl, C_1-C_6-alkyl aryl, C_2-C_6-alkenyl-aryl, C_2-C_6-alkynyl aryl, carboxy, cyano, hydroxy, C_1-C_6-alkoxy, nitro, acylamino, ureido, C_1-C_6-alkyl carbamate, sulfonylamino, sulfanyl, and sulfonyl

~~wherein R^1 and R^2 is as above defined~~.

Claim 24 (Currently Amended): A thiazolidinone-vinyl fused-benzene derivative according any of formulae (IV), (V) and (VI):



(IV)



(V)



(VI)

wherein R^1 is selected from the group consisting of hydrogen, halogen, cyano, C_1-C_6-alkyl, C_1-C_6-alkoxy, acyl, and alkoxy cabonyl, ~~while R^2 is as above defined~~ and

R^2 is selected from the group consisting of H, halogen, acyl, amino, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_6-alkyl carboxy, C_1-C_6-alkyl acyl, C_1-C_6-alkyl alkoxycarbonyl, C_1-C_6-alkyl aminocarbonyl, C_1-C_6-alkyl acyloxy, C_1-C_6-alkyl acylamino, C_1-C_6-alkyl ureido, C_1-C_6-alkyl amino, C_1-C_6-alkyl alkoxy, C_1-C_6-alkyl sulfanyl, C_1-C_6-alkyl sulfinyl, C_1-C_6-alkyl sulfonyl, C_1-C_6-alkyl sulfonylaminoaryl, aryl, C_3-C_8-cycloalkyl or heterocycloalkyl, C_1-C_6-alkyl aryl, C_2-C_6-alkenyl-aryl, C_2-C_6-alkynyl aryl, carboxy, cyano,

hydroxy, C_1-C_6-alkoxy, nitro, acylamino, ureido, C_1-C_6-alkyl carbamate, sulfonylamino, sulfanyl, and sulfonyl.

Claim 25 (Currently Amended): The ~~A~~ thiazolidinone-vinyl fused-benzene derivative according to claim 19, ~~any of claims 19 to 24~~ selected from the group consisting of:

5-(1,3-benzodioxol-5-ylmethylene)-1,3-thiazolidine-2,4-dione,

5-(1,3-benzodioxol-5-ylmethylene)-2-thioxo-1,3-thiazolidin-4-one,

5-(2,3-dihydro-1,4-benzodioxin-6-ylmethylene)-1,3-thiazolidine-2,4-dione,

5-(2,3-dihydro-1 -benzofuran-5-ylmethylene)-1,3-thiazolidine-2,4-dione,

5-[(7-methoxy-1,3-benzodioxol-5-yl)methylene]-1,3-thiazolidine-2,4-dione,

5-[(9,10-dioxo-9,10-dihydroanthracen-2-yl)methylene]-1,3-thiazolidine-2,4-dione,

(5-[(2,2-difluoro-1,3-benzodioxol-5-yl)methylene]-1,3-thiazolidine-2,4-dione,

(5Z)-5-(1,3-dihydro-2-benzofuran-5-ylmethylene)-1,3-thiazolidine-2,4-dione,

5-(1-benzofuran-5-ylmethylene)-1,3-thiazolidine-2,4-dione,

5-[(4-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)methylene]-1,3-thiazolidine-2,4-dione,

5-(1,3-benzodioxol-5-ylmethylene)-2-imino-1,3-thiazolidin-4-one,

5-Quinolin-6-ylmethylene-thiazolidine-2,4-dione,

5-Quinolin-6-ylmethylene-2-thioxo-thiazolidin-4-one,

2-Imino-5-quinolin-6-ylmethylene-thiazolidin-4-one,

5-(3-Methyl-benzo[d]isoxazol-5-ylmethylene)-thiazolidine-2,4-dione,

5-(4-Phenyl-quinazolin-6-ylmethylene)-thiazolidine-2,4-dione,

5-(4-Dimethylamino-quinazolin-6-ylmethylene)-thiazolidine-2,4-dione,

5-[(4-aminoquinazolin-6-yl)methylene]-1,3-thiazolidine-2,4-dione,

5-[(4-piperidin-l-ylquinazolin-6-yl)methylene]-1,3-thiazolidine-2,4-dione,

5-[(4-morpholin-4-ylquinazolin-6-yl)methylene]-1,3-thiazolidine-2,4-dione,

5-{[4-(benzylamino)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

5-{[4-(diethylamino)quinazolin-6-yl]methylene)-1,3-thiazolidine-2,4-dione,

5-({4-[(pyridin-2-ylmethyl)amino]quinazolin-6-yl}methylene)-1,3-thiazolidine-2,4-dione,

5-({4-[(pyridin-3-ylmethyl)amino]quinazolin-6-yl}methylene)-1,3-thiazolidine-2,4-dione,

ethyl l-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]quinazolin-4-yl}piperidine-3-carboxylate,

ethyl 1-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]quinazolin-4-yl)piperidine-4-carboxylate,

tert-butyl-1-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]quinazolin-4-yl)-L-prolinate,

5-{ [4-(4-methylpiperazin-1-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

5-{[4-(4-pyrimidin-2-ylpiperazin-1-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

5-({4-[4-(4-fluorophenyl)piperidin-1-yl]quinazolin-6-yl }methylene)-1,3-thiazolidine-2,4-dione,

5-{ [4-(4-benzylpiperidin-1-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

5-({4-[4-(2-phenylethyl)piperidin-l-y]]quinazolin-6-yl}methylene)-1,3-thiazolidine-2,4-dione,

5-{ [4-(4-methylpiperidin-l-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

5-{ [4-(4-hydroxypiperidin-l-yl)quinazolin-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

1-[6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-quinazolin-4-yl]-piperidine-4-carboxylic acid,

1-[6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-quinazolin-4-yl]-piperidine-3-carboxylic acid,

1-[6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-quinazolin-4-yl]-pyrrolidine-2-carboxylic acid,

5-(4-Methylamino-quinazolin-6-ylmethylene)-thiazolidine-2,4-dione,

5-(4-Methoxy-quinazolin-6-ylmethylene)-thiazolidine-2,4-dione

2-Imino-5-(4-methylamino-quinazolin-6-ylmethylene)-thiazolidin-4-one,

2-Imino-5-(4-piperidine-quinazolin-6-ylmethylene)-thiazolidin-4-one,

2-Imino-5-(4-dimethylamino-quinazolin-6-ylmethylene)-thiazolidin-4-one,

5-(2-Methyl-2H-benzotriazol-5-ylmethylene)-thiazolidine-2,4-dione,

5-(3-Methyl-3H-benzotriazol-5-ylmethylene)-thiazolidine-2,4-dione,

5-(3-Ethyl-3H-benzoimidazol-5-ylmethylene)-thiazolidine-2,4-dione,

5-{[l-(4-phenylbutyl)-1H-benzimidazol-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

5-[(1-prop-2-yn-1-yl-1H-benzimidazol-6-yl)methylene]-1,3-thiazolidine-2,4-dione,

5-[(1-{2-[4-(trifluoromethyl)phenyl] ethyl} -1H-benzimidazol-6-yl)methylene]-1,3-thiazolidine-2,4-dione,

5-({1-[2-(4-hydroxyphenyl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione,

methyl 4-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1H-benzimidazol-l-yl}cyclohexanecarboxylate,

5-({l-[2-(5-methoxy-1H-indol-3-yl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione,

5-({1-[(1-methyl-1H-pyrazol-4-yl)methyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione,

5-({1-[2-(3,4-dimethoxyphenyl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione,

5-({1-[2-(4-phenoxyphenyl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione,

5-({1-[4-(trifluoromethyl)benzyl]-1H-benzimidazol-6-yl }methylene)-1,3-thiazolidine-2,4-dione,

4-{6-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1H-benzimidazol-l-yl}cyclohexanecarboxylic acid,

5-[(1-isobutyl-1H-benzimidazol-6-yl)methylene]-1,3-thiazolidine-2,4-dione,

5-({1-[2-(1,3-benzodioxol-4-yl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione,

5-({1-[2-(2-phenoxyphenyl)ethyl]-1H-benzimidazol-6-yl}methylene)-1,3-thiazolidine-2,4-dione,

5-1[1-(3,3-diphenylpropyl)-1H-benzimidazol-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

5-{[1-(2-methoxybenzyl)-1H-benzimidazol-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

5- {[1-(3-furylmethyl)-1H-benzimidazol-6-yl]methylene}-1,3-thiazolidine-2,4-dione,

5-[(1-propyl-1H-benzimidazol-6-yl)methylene]-1,3-thiazolidine-2,4-dione,

5-Quinoxalin-6-ylmethylene-thiazolidine-2,4-dione,

5-Quinoxalin-6-ylmethylene-2-thioxo-thiazolidin-4-one,

2-Imino-5-quinoxalin-6-ylmethylene-thiazolidin-4-one,

5-Benzothiazol-6-ylmethylene-thiazolidine-2,4-dione,

5-(3-Methyl-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione,

5-(2-Bromo-3-methyl-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione,

5-(3-bromo-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione,

3-[5-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzofuran-3-yl]-acrylic acid ethyl ester,

3-[5-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzofuran-3-y]]-acrylic acid,

5-[3-(3-Oxo-3-piperidin-l-yl-propenyl)-benzofuran-5-ylmethylene]-thiazolidine-2,4-dione,

Methyl 1-((3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}prop-2-enoyl)prolinate,

Methyl 1-((3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}prop-2-enoyl)-D-prolinate,

(5-({3-[(3-oxo-3-pyrrolidin-1-ylprop-l-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione,

5-({3-[3-morpholin-4-yl-3-oxoprop-l-en-1-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione,

Methyl 1-(3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}prop-2-enoyl)-L-prolinate,

N-cyclohexyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl)-N-methylacrylamide,

3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}-N-ethyl-N-(2-hydroxyethyl)acrylamide,

N-cyclobutyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl} acrylamide,

5-({3-[3-azetidin-l-yl-3-oxoprop-l-en-l-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione,

5-({3-[3-(1,3-dihydro-2H-isoindol-2-yl)-3-oxoprop-l-en-l-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione,

5-({3-[3-azepan-l-yl-3-oxoprop-l-en-l-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione,

3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}-N-piperidin-l-ylacrylamide,

3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}-N-(pyridin-3-ylmethyl)acrylamide,

N-cyclohexyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl} acrylamide,

5-({3-[3-(4-methylpiperazin-l-yl)-3-oxoprop-l-en-l-yl]-1-benzofuran-5-yl}methylene)-1,3-thiazolidine-2,4-dione,

N-cycloheptyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}acrylamide,

5-({3-[3-(2,5-dihydro-1H-pyrrol-l-yl)-3-oxoprop-1-en-l-yl]-1-benzofuran-5-yl} methylene)-1,3-thiazolidine-2,4-dione,

N-cyclopentyl-3-{5-[(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-1-benzofuran-3-yl}acrylamide,

3-[5-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzofuran-3-yl]-propionic acid ethyl ester,

3-[5-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzofuran-3-yl]-propionic acid,

5-[3-(3-Oxo-3-piperidin-1-yl-propyl)-benzofuran-5-ylmethylene]-thiazolidine-2,4-dione,

6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-2,3-dihydro-benzo[1,4]oxazine-4-carboxylic acid tert-butyl ester,

5-(3,4-Dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione,

5-(4-Benzoyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione,

5-(4-Acetyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione,

6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-benzo[1,4]oxazine-4-carboxylic acid tert-butyl ester,

[6-(2,4-Dioxo-thiazolidin-5-ylidenemethyl)-3-oxo-2,3-dihydro-benzo[1,4]-oxazin-4-yl]-acetic acid methyl ester,

N-Benzyl-2-[6-(2,4-dioxo-thiazolidin-5-ylidenemethyl)-3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl]-acetamide,

~~5-(4-Butyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazoli-dine-2,4-dione~~

5-(4-Butyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione,

5-(4-Benzyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethylene)-thiazolidine-2,4-dione,

5-(2-Chloro-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione,

5-(3-Amino-benzo[d]isoxazol-5-ylmethylene)-thiazolidine-2,4-dione,

5-(3-Phenylethynyl-benzofuran-5-ylmethylene)-thiazolidine-2,4-dione,

5-Benzo[1,2,5]thiadiazol-5-ylmethylene-thiazolidine-2,4-dione,

5-Benzo[1,2,5]oxadiazol-5-ylmethylene-thiazolidine-2,4-dione,

5-(2-Methyl-benzofuran-6-ylmethylene)-thiazolidine-2,4-dione,

5-(2-Carboxymethyl-benzofuran-6-ylmethylene)-thiazolidine-2,4-dione,

5-(3-Bromo-2-fluoro-2,3-dihydro-benzofuran-6-ylmethylene)-thiazolidine-2,4-dione, and

5-(2-Fluoro-benzofuran-6-ylmethylene)-thiazolidine-2,4-dione.

Claim 26 (Currently Amended): A method of preparing a medicament, comprising, contacting the thiazolidinone-vinyl fused-benzene derivative according to claim 19, with one or more pharmaceutically acceptable additives ~~any of claims 19 to 25 for use as a medicament~~.

Claim 27 (Currently Amended): A pharmaceutical composition, comprising ~~containing~~ at least one thiazolidinone-vinyl fused-benzene derivative according to claim 19, ~~any of claims 19 to 25~~ and a pharmaceutically acceptable carrier, diluent or excipient thereof.

Claim 28 (Currently Amended): A method ~~Use of a thiazolidinone-vinyl fused-benzene derivative according to any of claims 19 to 25 for the preparation of a medicament~~ for the prophylaxis and/or treatment of one or more diseases or disorders, selected from autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, graft rejection or lung injuries, comprising, administering to a subject in need thereof, an effective amount of the thiazolidinone-vinyl fused-benzene derivative according to claim 19.

Claim 29 (Currently Amended): The method ~~Use of a thiazolidinone-vinyl fused-benzene derivative~~ according to claim 28, wherein said one or more diseases are selected from ~~in~~ the group consisting of ~~including~~ multiple sclerosis, psoriasis, rheumatoid arthritis, ~~multiple sclerosis~~[[,]] systemic lupus erythematosis, inflammatory bowel disease, lung inflammation, and thrombosis or brain infection/inflammation such as meningitis or encephalitis.

Claim 30 (Currently Amended): The method ~~Use of a thiazolidinone-vinyl fused-benzene derivative~~ according to claim 28, wherein the said one or more diseases are selected from ~~in~~ the group consisting of ~~including~~ Alzheimer's disease, Huntington's disease, CNS trauma, stroke and ~~or~~ ischemic conditions.

Claim 31 (Currently Amended): The method ~~Use of a thiazolidinone-vinyl fused-benzene derivative~~ according to claim 28, wherein said one or more diseases are selected from ~~in~~ the group consisting of ~~including~~ atherosclerosis, heart hypertrophy, cardiac myocyte dysfunction, elevated blood pressure and ~~or~~ vasoconstriction.

Claim 32 (Currently Amended): The method ~~Use of a thiazolidinone-vinyl fused-benzene derivative~~ according to claim 28, wherein said one or more diseases are selected from ~~in~~ the group consisting of ~~including~~ chronic obstructive pulmonary disease, anaphylactic shock fibrosis, psoriasis, allergic diseases, asthma, stroke or ischemic conditions, ischemia-reperfusion, platelets aggregation/activation, skeletal muscle atrophy/hypertrophy, leukocyte recruitment in cancer tissue, angiogenesis, invasion metastisis, ~~in particular~~ melanoma, Karposi's sarcoma, acute and chronic bacterial and viral infections, sepsis, transplantation, graft rejection, pancreatitis, multiorgane failure, glomerulo

sclerosis, glomerulo nephritis, progressive renal fibrosis, endothelial and epithelial injuries in the lung and ~~or in~~ general lung airways inflammation.

Claim 33 (Currently Amended): A method for the prophylaxis and/or treatment of one or more diseases mediated by PI3 kinase, comprising administering to a subject in need thereof, an effective amount of a thiazolidinone-vinyl fused-benzene derivative according to formula (II-a): ~~Use according to any of claims 28 to 32 for the modulation, particularly the inhibition of PI3Kinase activity~~



(II-a)

wherein A is selected from the group consisting of dioxol, dioxin, dihydrofuran, (dihydro) furanyl, (dihydro)oxazinyl, pyridinyl, isooxazolyl, oxazolyl (dihydro)napthalenyl, pyrimidinyl, triazolyl, imidazolyl, pyrazinyl, thiazolidinyl, thiadiazolyl, and oxadiazolyl;

R^2 is selected from the group consisting of H, halogen, acyl, amino, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_6-alkyl carboxy, C_1-C_6-alkyl acyl, C_1-C_6-alkyl alkoxycarbonyl, C_1-C_6-alkyl aminocarbonyl, C_1-C_6-alkyl acyloxy, C_1-C_6-alkyl acylamino, C_1-C_6-alkyl ureido, C_1-C_6-alkyl carbamate, C_1-C_6-alkyl amino, C_1-C_6-alkyl alkoxy, C_1-C_6-alkyl sulfanyl, C_1-C_6-alkyl sulfinyl, C_1-C_6-alkyl sulfonyl, C_1-C_6-alkyl sulfonylaminoaryl, aryl, C_3-C_8-cycloalkyl or heterocycloalkyl, C_1-C_6-alkyl aryl, C_2-C_6-alkenyl-aryl, C_2-C_6-alkynyl aryl, carboxy, cyano, hydroxy, C_1-C_6-alkoxy, nitro, acylamino, ureido, sulfonylamino, sulfanyl, and sulfonyl.

Claim 34 (Currently Amended): The method ~~Use~~ according to claim 33, wherein said PI3 Kinase ~~PI3Kinase~~ is a PI3 Kinase-γ ~~PI3Kinase-γ~~.

Claim 35 (Currently Amended): A method of preparing a thiazolidinone-vinyl fused-benzene ~~derivatives~~ derivative of formula ~~(I)~~ (II), according to claim 20, comprising the following step:



(II)

wherein R^1, R^2, Y^1, Z and n are as above defined in formula (II).

Claim 36 ~~33~~ (Currently Amended): A method of preparing a thiazolidinone-vinyl fused-benzene derivative ~~derivatives~~ of formula (III), according to claim 23, comprising the following step:



(III)

wherein R^1, R^2 ~~and Y^1~~ are as above defined for formula (III), and Y^1 is O, S or NH.

Claim 37 (New): A composition, comprising, a compound according to formula (I):



(I)

as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts and pharmaceutically active derivatives thereof, wherein

A is a 5-8 membered heterocyclic or carbocyclic group, wherein said carbocyclic group may be fused with aryl, heteroaryl, cycloalkyl or heterocycloalkyl;

X is S, O or NH;

Y^1 and Y^2 are independently S, O or NH;

Z is S or O;

R^1 is H, CN, carboxy, acyl, C_1-C_6-alkoxy, halogen, hydroxy, acyloxy, C_1-C_6-alkyl carboxy, C_1-C_6-alkyl acyloxy, C_1-C_6-alkyl alkoxy, alkoxycarbonyl, C_1-C_6-alkyl alkoxycarbonyl, aminocarbonyl, C_1-C_6-alkyl aminocarbonyl, acylamino, C_1-C_6-alkyl acylamino, ureido, C_1-C_6-alkyl ureido, amino, C_1-C_6-alkyl amino, ammonium, sulfonyloxy, C_1-C_6-alkyl sulfonyloxy, sulfonyl, C_1-C_6-alkyl sulfonyl, sulfinyl, C_1-C_6-alkyl sulfinyl, sulfanyl, C_1-C_6-alkyl sulfanyl, sulfonylamino, C_1-C_6-alkyl sulfonylamino or carbamate;

R^2 is selected from the group consisting of H, halogen, acyl, amino, C_1-C_6-alkyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, C_1-C_6-alkyl carboxy, C_1-C_6-alkyl acyl, C_1-C_6-alkyl alkoxycarbonyl, C_1-C_6-alkyl aminocarbonyl, C_1-C_6-alkyl acyloxy, C_1-C_6-alkyl acylamino, C_1-C_6-alkyl ureido, C_1-C_6-alkyl amino, C_1-C_6-alkyl alkoxy, C_1-C_6-alkyl sulfanyl, C_1-C_6-alkyl

sulfinyl, C_1-C_6-alkyl sulfonyl, C_1-C_6-alkyl sulfonylaminoaryl, aryl, C_3-C_8-cycloalkyl or heterocycloalkyl, C_1-C_6-alkyl aryl, C_2-C_6-alkenyl-aryl, C_2-C_6-alkynyl aryl, carboxy, cyano, hydroxy, C_1-C_6-alkoxy, nitro, acylamino, ureido, C_1-C_6-alkyl carbamate, sulfonylamino, sulfanyl, or sulfonyl;

n is 0, 1 or 2;

with the proviso that the following compounds are excluded:



(TE)



(JA)

wherein R^1 is a lower alkyl or aralkyl and R^2 is H or a halogen.